Reverse Medical Corporation commences human use of its ReStore Microcatheter

NewsGuard 100/100 Score

Reverse Medical Corporation announced today they have initiated human use of their ReStore™ Microcatheter for reestablishing blood flow in the Neurovasculature. The device was successfully used in an acute ischemic stroke patient in Germany.

Commenting on this significant clinical milestone, Reverse Medical’s President and Chief Executive Officer Jeffrey Valko said, “Human use is always a major milestone to achieve, and the success of the ReStore Microcatheter has now validated our pre-clinical experiences. Demonstrating safety and device performance in the clinical setting will continue to build a strong foundation for accelerating enrollment into our 2010 clinical trial supporting a FDA 510k clearance. Reverse Medical will continue to pursue a broadening platform of state-of-the-art endovascular devices for the treatment of neurovascular disorders.”

Reverse Medical has received enthusiastic support from numerous European centers who have been trained to date on the new technology. Comments from the Company’s lead physician related to the human use experience include, “It is a very clever design and intuitive for use. The options for quickly reestablishing blood flow past the clot, infusing into the clot, or performing thrombectomy, all from one device is very appealing and a clear advancement over other devices for treating acute ischemic stroke patients.”

Source:

Reverse Medical Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The hidden struggle of lateropulsion in stroke survivors